Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1

Conditions

Rectal Neoplasms 1Prostatic Neoplasms 1Neoplasms 1

Interventions

Capecitabine 13Oxaliplatin 10Radiotherapy 8Surgical Procedures, Operative 6Drug Therapy 5tislelizumab 4Irinotecan 4sintilimab 3Neoadjuvant Therapy 3Immunotherapy 3Fluorouracil 3Endoscopic Mucosal Resection 3Bevacizumab 3spartalizumab 2raltitrexed 2XELOX 2Trinitrotoluene 2Radiation 2Immune Checkpoint Inhibitors 2Folfox protocol 2Cetuximab 2toripalimab 1sperm releasing substance 1saxagliptin 1s-formylglutathione hydrolase 1envafolimab 1disitamab vedotin 1cemiplimab 1camrelizumab 1balstilimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Rectal Neoplasms × Rifaximin × Clear all
NCT06783153 2025-01-20

Efficacy and Safety of Adjunctive Use of Rifaximin In Preventing Radiotherapy-induced Diarrhea in Cancer Patients

Mansoura University

Phase 1/2 Not yet recruiting
80 enrolled
GastrointestinalGenitourinary

Neoplasms, Prostatic Neoplasms, Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡